The University of California, San Francisco (UCSF) has entered into a partnership with Pfizer to reduce the time required to translate promising biomedical research into effective medications and therapies.

The partnership, which could support up to ten projects at a time, will create an open network of researchers called the Center for Therapeutic Innovation (CTI).

The CTI will enable the UCSF and Pfizer scientists to identify promising experimental molecules and rapidly move them into proof-of-concept studies and clinical trials.

Under the agreement, UCSF will receive $85m in research and milestone payments over the next five years if the collaboration leads to the development of new therapies for diseases with unmet clinical need.